Klaria Pharma Holding

Klaria Pharma Holding AB is a Swedish pharmaceutical company built around its patented Alginate Film drug-delivery platform, which places well-known active substances in a rapidly dissolving oral film that attaches to the mucosa. The group develops product candidates and combination products for therapeutic areas such as migraine, opioid overdose, anaphylactic shock, cancer-related pain, and other acute conditions, with operations centered in Sweden through its subsidiary structure.

— Klaria Pharma Holding
%
Drug-delivery platform0% Patented oral mucosal film technology used to deliver active pharmaceutical ingredients.
Migraine products25% Sumatriptan-based film formulations developed for migraine treatment.
Opioid overdose products20% Naloxone film formulations intended for emergency overdose reversal use.
Anaphylaxis products20% Epinephrine film formulations designed for rapid treatment of severe allergic reactions.
Pain and CNS products35% Ketamine and cannabinoid-based film projects for pain and related indications.

Klaria’s customers are primarily pharmaceutical partners, licensees, distributors, and other commercial counterparties...

  • Pharmaceutical partnersprimary

    Companies that collaborate on development, licensing, or commercialization of film-based drug candidates.

  • Distributors and commercial partnersprimary

    Organizations that help bring approved products to market and expand geographic reach.

  • Healthcare systems and providerssecondary

    Hospitals, clinics, and emergency-care settings that would use rapid-acting therapies if approved and launched.

  • Patients in acute indicationssecondary

    End users for migraine, opioid overdose, anaphylaxis, and pain products once commercialized.

  • Research and development collaboratorssecondary

    Counterparties involved in clinical, regulatory, and formulation work around specific product candidates.

Klaria is headquartered in Sweden and listed on Nasdaq First North Growth Market in Stockholm...

  • •Headquartered in Sweden with group operations centered there
  • •Listed on Nasdaq First North Growth Market in Stockholm
  • •Patent coverage spans Sweden, the EU/rest of world, and the US
  • •Commercial opportunity is international because drug approvals are market-specific
  • •Regulatory exposure differs by region due to FDA, EMA, and local authorities

Klaria’s strategy is to protect and extend its Alginate Film platform through a patent portfolio and project-specific...

01
Expand and defend intellectual propertymedium-term

Patent protection is central to preserving the platform's commercial value and partner appeal.

02
Advance product candidates in high-need indicationsmedium-term

The company’s value depends on converting the platform into approved, marketable products.

03
Build partnerships for development and commercializationshort-term

External partners are important for funding, market access, and execution across regions.

Klaria faces the typical risks of a development-stage pharmaceutical company: regulatory approval uncertainty, clinical...

critical

Regulatory approval risk

Products require clinical evidence and approvals from authorities such as the FDA and EMA before sales can begin.

Scope
Product candidates in multiple therapeutic areas
Materiality
high
high

Clinical development and manufacturing risk

The company must prove safety, efficacy, and manufacturability for each candidate and market.

Scope
All pipeline programs
Materiality
high
high

Intellectual property risk

Patent coverage may be incomplete, challenged, or insufficient to block competitors.

Scope
Alginate Film platform and combination patents
Materiality
high
high

Partner and distribution risk

Growth depends on agreements with distributors and other commercial counterparties.

Scope
Commercialization and market access
Materiality
medium
medium

Competition risk

Other companies may develop equivalent or better products for the same indications.

Scope
Migraine, overdose reversal, allergy, and pain markets
Materiality
medium
IFRS 15
IFRS 15 revenue recognition
Affects timing and comparability of reported sales
Impairment of intangible assets
Can create material non-cash charges
Deferred tax assets and loss carryforwards
Affects tax asset recognition and equity
Equity and capital structure
Dilution and balance-sheet resilience

Connect Biopharma Holdings Ltd

CNTB · Pharmaceutical Preparations

Lyra Therapeutics, Inc.

LYRA · Surgical & Medical Instruments & Apparatus

Karyopharm Therapeutics Inc.

KPTI · Pharmaceutical Preparations

Citius Pharmaceuticals, Inc.

CTXR · Pharmaceutical Preparations

Scilex Holding Co

SCLX · Biological Products, (No Diagnostic Substances)

Clearside Biomedical, Inc.

CLSDQ · Pharmaceutical Preparations

: 11/08/2026